Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral MLN9708 in Patients With Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors With Normal Renal Function or Severe Renal Impairment
Sponsor: Millennium Pharmaceuticals, Inc.
This PHASE1 trial investigates Advanced Solid Tumors and Multiple Myeloma and is currently completed. Millennium Pharmaceuticals, Inc. leads this study, which shows 9 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Jul 2019 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jun 2017 — Sep 2017 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2017 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Sep 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Millennium Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Atlanta, United States, Baltimore, United States, Dallas, United States, Fairway, United States, Laredo, United States, Nashville, United States, New York, United States, Oklahoma City, United States, Peoria, United States, San Antonio, United States and 1 more location